MASP2 and Genetic thrombotic microangiopathy: In hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA), plasma MASP-2 levels are elevated versus healthy controls, and narsoplimab has been shown to reduce HSCT-TMA plasma-mediated endothelial damage in a tissue culture model (52).